SCHEMBL19641204

SCHEMBL19641204

CC(C)(C)OC(=O)N1CCC2(CC1)CCC(F)(F)/C2=N\[S+]([O-])C(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ EPHX2 P34913 1/20 0.35
▸ USP30 Q70CQ3 1/20 0.34
▸ MAPT P10636 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ THRB P10828 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ GPR119 Q8TDV5 6/20 0.34
▸ HRH3 Q9Y5N1 2/20 0.33
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC8 Q9BY41 1/20 0.33
▸ HDAC6 Q9UBN7 1/20 0.33
▸ TACR1 P25103 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ ATM Q13315 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19641205 1.00 USP2 (0.37) USP2SMN1; SMN2EPHX2USP30MAPT
SCHEMBL31336522 0.81 USP2 (0.38) USP2SMN1; SMN2EPHX2USP30MAPT
SCHEMBL29366691 0.81 USP2 (0.38) USP2SMN1; SMN2EPHX2USP30MAPT
SCHEMBL29959213 0.79 USP2 (0.37) USP2SMN1; SMN2USP30MAPTKDM4E
SCHEMBL18320481 0.79 USP2 (0.37) USP2SMN1; SMN2USP30MAPTKDM4E
SCHEMBL31184416 0.79 USP2 (0.37) USP2SMN1; SMN2USP30MAPTKDM4E
SCHEMBL20337484 0.79 USP2 (0.37) USP2SMN1; SMN2USP30MAPTKDM4E
SCHEMBL16925177 0.78 USP2 (0.45) USP2SMN1; SMN2EPHX2USP30MAPT
SCHEMBL30577842 0.77 CHRM2 (0.35) USP2SMN1; SMN2USP30MAPTKDM4E
SCHEMBL18320482 0.76 ESR2 (0.34) USP2SMN1; SMN2USP30MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11840536-B2 Heterocyclic inhibitors of PTPN11 BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-12-12 — — US disclosed
US-20230109858-A1 HETEROCYCLIC INHIBITORS OF PTPN11 BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2023-04-13 — — US disclosed
US-11466017-B2 Heterocyclic inhibitors of PTPN11 BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-10-11 — — US disclosed
EP-3463343-B1 HETEROCYCLIC INHIBITORS OF PTPN11 UNIV TEXAS (US) 2022-03-23 — — EP disclosed
US-20210017182-A1 HETEROCYCLIC INHIBITORS OF PTPN11 BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2021-01-21 — — US disclosed
US-10851110-B2 Heterocyclic inhibitors of PTPN11 BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2020-12-01 — — US disclosed
US-20190270746-A1 HETEROCYCLIC INHIBITORS OF PTPN11 BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2019-09-05 — — US disclosed
US-10280171-B2 Heterocyclic inhibitors of PTPN11 BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-05-07 — — US disclosed
EP-3463343-A1 HETEROCYCLIC INHIBITORS OF PTPN11 Board of Regents, University of Texas System (US) 2019-04-10 — — EP disclosed
WO-2017210134-A1 HETEROCYCLIC INHIBITORS OF PTPN11 BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) 2017-12-07 — — WO disclosed
US-20170342078-A1 HETEROCYCLIC INHIBITORS OF PTPN11 BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2017-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170342078-A1 HETEROCYCLIC INHIBITORS OF PTPN11 PTPRJ, PTPN11, PTPRCAP USP2 1045/4885SMN1; SMN2 4183/4885EPHX2 2536/4885
US-11466017-B2 Heterocyclic inhibitors of PTPN11 PTPRJ, PTPN11, PTPRCAP USP2 1045/4885SMN1; SMN2 4183/4885EPHX2 2536/4885
US-20210017182-A1 HETEROCYCLIC INHIBITORS OF PTPN11 PTPRJ, PTPN11, PTPRCAP USP2 1045/4885SMN1; SMN2 4183/4885EPHX2 2536/4885
US-20230109858-A1 HETEROCYCLIC INHIBITORS OF PTPN11 PTPRJ, PTPN11, PTPRCAP USP2 1045/4885SMN1; SMN2 4183/4885EPHX2 2536/4885
US-10851110-B2 Heterocyclic inhibitors of PTPN11 PTPRJ, PTPN11, PTPRCAP USP2 1045/4885SMN1; SMN2 4183/4885EPHX2 2536/4885
US-20190270746-A1 HETEROCYCLIC INHIBITORS OF PTPN11 PTPRJ, PTPN11, PTPRCAP USP2 1045/4885SMN1; SMN2 4183/4885EPHX2 2536/4885
US-10280171-B2 Heterocyclic inhibitors of PTPN11 PTPRJ, PTPN11, PTPRCAP USP2 1045/4885SMN1; SMN2 4183/4885EPHX2 2536/4885
US-11840536-B2 Heterocyclic inhibitors of PTPN11 PTPRJ, PTPN11, PTPRCAP USP2 1045/4885SMN1; SMN2 4183/4885EPHX2 2536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback